Latest news and press releases about BioVie Inc. (BIVI): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis.
Price
| Price | $1.72 |
| Market Cap | $13M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.29 |
| EV / EBITDA | -0.31 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -126.02% |
| Return on Invested Capital | -214.80% |
| Return on Assets | -154.89% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTL · CANF · CERO · ELAB · GLMD · INM · KZIA
Explore sector: Healthcare · Biotechnology
More sections of BIVI: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks